Literature DB >> 20083199

Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease.

Miranda L Bader Lange1, Daret St Clair, William R Markesbery, Christa M Studzinski, M Paul Murphy, D Allan Butterfield.   

Abstract

Using APP(NLh)/APP(NLh) x PS-1(P246L)/PS-1(P246L) human double knock-in (APP/PS-1) mice, we examined whether phosphatidylserine (PtdSer) asymmetry is significantly altered in brain of this familial Alzheimer disease mouse model in an age-dependent manner as a result of oxidative stress, toxic Abeta(1-42) oligomer production, and/or apoptosis. Annexin V (AV) and NBD-PS fluorescence in synaptosomes of wild-type (WT) and APP/PS-1 mice were used to determine PtdSer exposure with age, while Mg(2+) ATPase activity was determined to correlate PtdSer asymmetry changes with PtdSer translocase, flippase, activity. AV and NBD-PS results demonstrated significant PtdSer exposure beginning at 9 months compared to 1-month-old WT controls for both assays, a trend that was exacerbated in synaptosomes of APP/PS-1 mice. Decreasing Mg(2+) ATPase activity confirms that the age-related loss of PtdSer asymmetry is likely due to loss of flippase activity, more prominent in APP/PS-1 brain. Two-site sandwich ELISA on SDS- and FA-soluble APP/PS-1 brain fractions were conducted to correlate Abeta(1-40) and Abeta(1-42) levels with age-related trends determined from the AV, NBD-PS, and Mg(2+) ATPase assays. ELISA revealed a significant increase in both SDS- and FA-soluble Abeta(1-40) and Abeta(1-42) with age, consistent with PtdSer and flippase assay trends. Lastly, because PtdSer exposure is affected by pro-apoptotic caspase-3, levels of both latent and active forms were measured. Western blotting results demonstrated an increase in both active fragments of caspase-3 with age, while levels of pro-caspase-3 decrease. These results are discussed with relevance to loss of lipid asymmetry and consequent neurotoxicity in brain of subjects with Alzheimer disease. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20083199      PMCID: PMC2834848          DOI: 10.1016/j.nbd.2010.01.004

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  79 in total

1.  Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.

Authors:  Pritam Das; Victor Howard; Nicole Loosbrock; Dennis Dickson; M Paul Murphy; Todd E Golde
Journal:  J Neurosci       Date:  2003-09-17       Impact factor: 6.167

2.  Docosahexaenoic acid stabilizes soluble amyloid-beta protofibrils and sustains amyloid-beta-induced neurotoxicity in vitro.

Authors:  Ann-Sofi Johansson; Anita Garlind; Fredrik Berglind-Dehlin; Göran Karlsson; Katarina Edwards; Pär Gellerfors; Frida Ekholm-Pettersson; Jan Palmblad; Lars Lannfelt
Journal:  FEBS J       Date:  2007-01-12       Impact factor: 5.542

3.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 4.  Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress.

Authors:  D Allan Butterfield; Christopher M Lauderback
Journal:  Free Radic Biol Med       Date:  2002-06-01       Impact factor: 7.376

5.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

6.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

7.  Amyloid peptides are toxic via a common oxidative mechanism.

Authors:  D Schubert; C Behl; R Lesley; A Brack; R Dargusch; Y Sagara; H Kimura
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

8.  Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid beta-protein 42 in the brain.

Authors:  F Oyama; N Sawamura; K Kobayashi; M Morishima-Kawashima; T Kuramochi; M Ito; T Tomita; K Maruyama; T C Saido; T Iwatsubo; A Capell; J Walter; J Grünberg; Y Ueyama; C Haass; Y Ihara
Journal:  J Neurochem       Date:  1998-07       Impact factor: 5.372

9.  Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease.

Authors:  Hafiz Mohmmad Abdul; Rukhsana Sultana; Jeffrey N Keller; Daret K St Clair; William R Markesbery; D Allan Butterfield
Journal:  J Neurochem       Date:  2006-03       Impact factor: 5.372

10.  Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease.

Authors:  Guna S D Moses; Michael D Jensen; Lih-Fen Lue; Douglas G Walker; Albert Y Sun; Agnes Simonyi; Grace Y Sun
Journal:  J Neuroinflammation       Date:  2006-10-07       Impact factor: 8.322

View more
  16 in total

Review 1.  Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies.

Authors:  Aaron M Swomley; Sarah Förster; Jierel T Keeney; Judy Triplett; Zhaoshu Zhang; Rukhsana Sultana; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2013-10-09

Review 2.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

3.  Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β.

Authors:  Liqin Qi; Zhou Chen; Yanping Wang; Xiaoying Liu; Xiaohong Liu; Linfang Ke; Zhongjie Zheng; Xiaowei Lin; Yu Zhou; Lijuan Wu; Libin Liu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

4.  Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) × PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age.

Authors:  Rukhsana Sultana; Renã A S Robinson; Fabio Di Domenico; Hafiz Mohmmad Abdul; Daret K St Clair; William R Markesbery; Jian Cai; William M Pierce; D Allan Butterfield
Journal:  J Proteomics       Date:  2011-06-25       Impact factor: 4.044

Review 5.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

Review 6.  4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies.

Authors:  Marzia Perluigi; Raffaella Coccia; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2012-02-15       Impact factor: 8.401

Review 7.  Oxidative stress and β-amyloid protein in Alzheimer's disease.

Authors:  Zhiyou Cai; Bin Zhao; Anna Ratka
Journal:  Neuromolecular Med       Date:  2011-09-08       Impact factor: 3.843

Review 8.  The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.

Authors:  D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-07-01       Impact factor: 7.376

Review 9.  Pathology supported genetic testing and treatment of cardiovascular disease in middle age for prevention of Alzheimer's disease.

Authors:  Maritha J Kotze; Susan J van Rensburg
Journal:  Metab Brain Dis       Date:  2012-04-19       Impact factor: 3.584

10.  Primary phagocytosis of neurons by inflamed microglia: potential roles in neurodegeneration.

Authors:  Jonas J Neher; Urte Neniskyte; Guy C Brown
Journal:  Front Pharmacol       Date:  2012-02-28       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.